Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study
Identifieur interne : 004A62 ( Main/Merge ); précédent : 004A61; suivant : 004A63Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study
Auteurs : Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lledo [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne]Source :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Dopamine agonists are used as initial treatment in patients with Parkinson's disease (PD) to reduce incidence and severity of motor complications. This paradigm is based on long-term studies, allowing "rescue" therapy with levodopa. The present strict monotherapy study (PELMOPET, the acronym for the pergolide-versus-L-dopa-monotherapy-and-positron-emission-tomography trial) evaluated the efficacy and safety of pergolide versus levodopa without levodopa "rescue" medication. This multicenter, double-blind, randomized, 3-year trial compared pergolide monotherapy (n = 148) with levodopa monotherapy (n = 146) in dopamine-naive patients with early PD (Hoehn and Yahr stage 1-2.5). Primary efficacy measures were clinical efficacy, severity and time to onset of motor complications, and disease progression. During the 3 years, severity of motor complications was significantly lower and time to onset of dyskinesia was significantly delayed in the group receiving pergolide (3.23 mg/ day) compared with those receiving levodopa (504 mg/day). However, time to onset of motor complications was not longer in patients receiving pergolide after 3 years. Symptomatic relief (assessed by Unified Parkinson's Disease Rating Scale [UPDRS], UPDRS II, and III, Clinical Global Impressions [CGI] severity, and CGI and Patient Global Impressions [PGI] improvement) was significantly greater in patients receiving levodopa. Adverse events led to discontinuation of therapy in 17.6% of pergolide patients and 9.6% of levodopa patients. This is the first study comparing strict monotherapy with a dopamine agonist versus levodopa in previously untreated early PD. In principle, both levodopa and a dopamine agonist such as pergolide seem to be suitable options as initial PD therapy. The choice remains with the treating physician based on the different efficacy and adverse event profiles.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 001C02
- to stream PascalFrancis, to step Curation: 001119
- to stream PascalFrancis, to step Checkpoint: 001967
Links to Exploration step
Pascal:06-0208442Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study</title><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, Philipps-University</s1><s2>Marburg</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Instituto de Farmacologia e Terapêutica Geral, Faculdade de Medicina de Lisboa, Hospital de Santa Maria</s1><s2>Lisbon</s2><s3>PRT</s3><sZ>3 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Gimenez Roldan, Santiago" sort="Gimenez Roldan, Santiago" uniqKey="Gimenez Roldan S" first="Santiago" last="Gimenez-Roldan">Santiago Gimenez-Roldan</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neurology, University Gregorio Maranon</s1><s2>Madrid</s2><s3>ESP</s3><sZ>4 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bergamasco, Bruno" sort="Bergamasco, Bruno" uniqKey="Bergamasco B" first="Bruno" last="Bergamasco">Bruno Bergamasco</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University Hospital</s1><s2>Turino</s2><s3>ITA</s3><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Turino</wicri:noRegion></affiliation></author><author><name sortKey="Dujardin, Max" sort="Dujardin, Max" uniqKey="Dujardin M" first="Max" last="Dujardin">Max Dujardin</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology</s1><s2>Evreux</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="région">Haute-Normandie</region><settlement type="city">Évreux</settlement></placeName></affiliation></author><author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institute of Neurology, Southern General Hospital</s1><s2>Glasgow, Scotland</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Glasgow, Scotland</wicri:noRegion></affiliation></author><author><name sortKey="Arnold, Guy" sort="Arnold, Guy" uniqKey="Arnold G" first="Guy" last="Arnold">Guy Arnold</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Neurology, Charite</s1><s2>Berlin</s2><s3>DEU</s3><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Neurology, University Hospital Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Hundemer, Hans Peter" sort="Hundemer, Hans Peter" uniqKey="Hundemer H" first="Hans-Peter" last="Hundemer">Hans-Peter Hundemer</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Lledo, Alberto" sort="Lledo, Alberto" uniqKey="Lledo A" first="Alberto" last="Lledo">Alberto Lledo</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Wood, Andrew" sort="Wood, Andrew" uniqKey="Wood A" first="Andrew" last="Wood">Andrew Wood</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Frewer, Paul" sort="Frewer, Paul" uniqKey="Frewer P" first="Paul" last="Frewer">Paul Frewer</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Neurology, University Hospital Leipzig</s1><s2>Leipzig</s2><s3>DEU</s3><sZ>14 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Leipzig</region><settlement type="city">Leipzig</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0208442</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0208442 INIST</idno><idno type="RBID">Pascal:06-0208442</idno><idno type="wicri:Area/PascalFrancis/Corpus">001C02</idno><idno type="wicri:Area/PascalFrancis/Curation">001119</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001967</idno><idno type="wicri:doubleKey">0885-3185:2006:Oertel W:pergolide:versus:levodopa</idno><idno type="wicri:Area/Main/Merge">004A62</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study</title><author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Neurology, Philipps-University</s1><s2>Marburg</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Neurology, VU University Medical Center</s1><s2>Amsterdam</s2><s3>NLD</s3><sZ>2 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Instituto de Farmacologia e Terapêutica Geral, Faculdade de Medicina de Lisboa, Hospital de Santa Maria</s1><s2>Lisbon</s2><s3>PRT</s3><sZ>3 aut.</sZ></inist:fA14><country>Portugal</country><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Gimenez Roldan, Santiago" sort="Gimenez Roldan, Santiago" uniqKey="Gimenez Roldan S" first="Santiago" last="Gimenez-Roldan">Santiago Gimenez-Roldan</name><affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Department of Neurology, University Gregorio Maranon</s1><s2>Madrid</s2><s3>ESP</s3><sZ>4 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bergamasco, Bruno" sort="Bergamasco, Bruno" uniqKey="Bergamasco B" first="Bruno" last="Bergamasco">Bruno Bergamasco</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, University Hospital</s1><s2>Turino</s2><s3>ITA</s3><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Turino</wicri:noRegion></affiliation></author><author><name sortKey="Dujardin, Max" sort="Dujardin, Max" uniqKey="Dujardin M" first="Max" last="Dujardin">Max Dujardin</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology</s1><s2>Evreux</s2><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14><country>France</country><placeName><region type="région">Haute-Normandie</region><settlement type="city">Évreux</settlement></placeName></affiliation></author><author><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name><affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Institute of Neurology, Southern General Hospital</s1><s2>Glasgow, Scotland</s2><s3>GBR</s3><sZ>7 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Glasgow, Scotland</wicri:noRegion></affiliation></author><author><name sortKey="Arnold, Guy" sort="Arnold, Guy" uniqKey="Arnold G" first="Guy" last="Arnold">Guy Arnold</name><affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Department of Neurology, Charite</s1><s2>Berlin</s2><s3>DEU</s3><sZ>8 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name><affiliation wicri:level="3"><inist:fA14 i1="09"><s1>Department of Neurology, University Hospital Groningen</s1><s2>Groningen</s2><s3>NLD</s3><sZ>9 aut.</sZ></inist:fA14><country>Pays-Bas</country><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Hundemer, Hans Peter" sort="Hundemer, Hans Peter" uniqKey="Hundemer H" first="Hans-Peter" last="Hundemer">Hans-Peter Hundemer</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Lledo, Alberto" sort="Lledo, Alberto" uniqKey="Lledo A" first="Alberto" last="Lledo">Alberto Lledo</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Wood, Andrew" sort="Wood, Andrew" uniqKey="Wood A" first="Andrew" last="Wood">Andrew Wood</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Frewer, Paul" sort="Frewer, Paul" uniqKey="Frewer P" first="Paul" last="Frewer">Paul Frewer</name><affiliation wicri:level="2"><inist:fA14 i1="10"><s1>Eli Lilly and Company</s1><s2>Indianapolis, Indiana</s2><s3>USA</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Indiana</region></placeName></affiliation></author><author><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name><affiliation wicri:level="3"><inist:fA14 i1="11"><s1>Department of Neurology, University Hospital Leipzig</s1><s2>Leipzig</s2><s3>DEU</s3><sZ>14 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="1">Saxe (Land)</region><region type="district" nuts="2">District de Leipzig</region><settlement type="city">Leipzig</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Comparative study</term><term>Complication</term><term>Dyskinesia</term><term>Human</term><term>Levodopa</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Pergolide</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Dyskinésie</term><term>Pergolide</term><term>Etude comparative</term><term>Lévodopa</term><term>Homme</term><term>Complication</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine agonists are used as initial treatment in patients with Parkinson's disease (PD) to reduce incidence and severity of motor complications. This paradigm is based on long-term studies, allowing "rescue" therapy with levodopa. The present strict monotherapy study (PELMOPET, the acronym for the pergolide-versus-L-dopa-monotherapy-and-positron-emission-tomography trial) evaluated the efficacy and safety of pergolide versus levodopa without levodopa "rescue" medication. This multicenter, double-blind, randomized, 3-year trial compared pergolide monotherapy (n = 148) with levodopa monotherapy (n = 146) in dopamine-naive patients with early PD (Hoehn and Yahr stage 1-2.5). Primary efficacy measures were clinical efficacy, severity and time to onset of motor complications, and disease progression. During the 3 years, severity of motor complications was significantly lower and time to onset of dyskinesia was significantly delayed in the group receiving pergolide (3.23 mg/ day) compared with those receiving levodopa (504 mg/day). However, time to onset of motor complications was not longer in patients receiving pergolide after 3 years. Symptomatic relief (assessed by Unified Parkinson's Disease Rating Scale [UPDRS], UPDRS II, and III, Clinical Global Impressions [CGI] severity, and CGI and Patient Global Impressions [PGI] improvement) was significantly greater in patients receiving levodopa. Adverse events led to discontinuation of therapy in 17.6% of pergolide patients and 9.6% of levodopa patients. This is the first study comparing strict monotherapy with a dopamine agonist versus levodopa in previously untreated early PD. In principle, both levodopa and a dopamine agonist such as pergolide seem to be suitable options as initial PD therapy. The choice remains with the treating physician based on the different efficacy and adverse event profiles.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Espagne</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>Portugal</li><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Berlin</li><li>Communauté de Madrid</li><li>District de Giessen</li><li>District de Leipzig</li><li>Groningue (province)</li><li>Haute-Normandie</li><li>Hesse (Land)</li><li>Hollande-Septentrionale</li><li>Indiana</li><li>Saxe (Land)</li></region><settlement><li>Amsterdam</li><li>Berlin</li><li>Groningue</li><li>Leipzig</li><li>Madrid</li><li>Marbourg</li><li>Évreux</li></settlement></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name></region><name sortKey="Arnold, Guy" sort="Arnold, Guy" uniqKey="Arnold G" first="Guy" last="Arnold">Guy Arnold</name><name sortKey="Schwarz, Johannes" sort="Schwarz, Johannes" uniqKey="Schwarz J" first="Johannes" last="Schwarz">Johannes Schwarz</name></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Wolters, Erik" sort="Wolters, Erik" uniqKey="Wolters E" first="Erik" last="Wolters">Erik Wolters</name></region><name sortKey="Leenders, Klaus L" sort="Leenders, Klaus L" uniqKey="Leenders K" first="Klaus L." last="Leenders">Klaus L. Leenders</name></country><country name="Portugal"><noRegion><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Gimenez Roldan, Santiago" sort="Gimenez Roldan, Santiago" uniqKey="Gimenez Roldan S" first="Santiago" last="Gimenez-Roldan">Santiago Gimenez-Roldan</name></region></country><country name="Italie"><noRegion><name sortKey="Bergamasco, Bruno" sort="Bergamasco, Bruno" uniqKey="Bergamasco B" first="Bruno" last="Bergamasco">Bruno Bergamasco</name></noRegion></country><country name="France"><region name="Haute-Normandie"><name sortKey="Dujardin, Max" sort="Dujardin, Max" uniqKey="Dujardin M" first="Max" last="Dujardin">Max Dujardin</name></region></country><country name="Royaume-Uni"><noRegion><name sortKey="Grosset, Donald G" sort="Grosset, Donald G" uniqKey="Grosset D" first="Donald G." last="Grosset">Donald G. Grosset</name></noRegion></country><country name="États-Unis"><region name="Indiana"><name sortKey="Hundemer, Hans Peter" sort="Hundemer, Hans Peter" uniqKey="Hundemer H" first="Hans-Peter" last="Hundemer">Hans-Peter Hundemer</name></region><name sortKey="Frewer, Paul" sort="Frewer, Paul" uniqKey="Frewer P" first="Paul" last="Frewer">Paul Frewer</name><name sortKey="Lledo, Alberto" sort="Lledo, Alberto" uniqKey="Lledo A" first="Alberto" last="Lledo">Alberto Lledo</name><name sortKey="Wood, Andrew" sort="Wood, Andrew" uniqKey="Wood A" first="Andrew" last="Wood">Andrew Wood</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004A62 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 004A62 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:06-0208442
|texte= Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study
}}
| This area was generated with Dilib version V0.6.23. |  |